Author: Giuseppe Gritti; Federico Raimondi; Diego Ripamonti; Ivano Riva; Francesco Landi; Leonardo Alborghetti; Marco Frigeni; Marianna Damiani; Caterina Micò; Stefano Fagiuoli; Roberto Cosentini; Ferdinando Luca Lorini; Fabrizio Fabretti; Jonathan Morgan; Benjamin M.J. Owens; Karan Kanhai; Jim Cowburn; Marco Rizzi; Fabiano Di Marco; Alessandro Rambaldi
Title: Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support Document date: 2020_4_3
ID: ajurlkwr_2
Snippet: This analysis is presented to inform the medical community of the potential role of siltuximab in treating patients with ARDS secondary to SARS-CoV-2 infection, and a cohort study with patients treated with standard therapy in our hospital is ongoing, and will report the 30-day mortality rates upon completion......
Document: This analysis is presented to inform the medical community of the potential role of siltuximab in treating patients with ARDS secondary to SARS-CoV-2 infection, and a cohort study with patients treated with standard therapy in our hospital is ongoing, and will report the 30-day mortality rates upon completion.
Search related documents:
Co phrase search for related documents- mortality rate and patient treat: 1, 2, 3
- mortality rate and potential role: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- mortality rate and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- mortality rate and standard therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
- mortality rate report and SARS infection: 1, 2, 3, 4
- patient treat and potential role: 1
- patient treat and SARS infection: 1, 2, 3, 4, 5, 6
- potential role and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- potential role and siltuximab potential role: 1, 2
- potential role and siltuximab potential role medical community: 1, 2
- potential role and siltuximab potential role medical community inform: 1, 2
- potential role and standard therapy: 1, 2, 3, 4
- SARS infection and siltuximab potential role: 1, 2
- SARS infection and siltuximab potential role medical community: 1, 2
- SARS infection and siltuximab potential role medical community inform: 1, 2
- SARS infection and standard therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- siltuximab potential role and standard therapy: 1, 2
- siltuximab potential role medical community and standard therapy: 1, 2
- siltuximab potential role medical community inform and standard therapy: 1, 2
Co phrase search for related documents, hyperlinks ordered by date